BTAI
BioXcel Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.07
−37.11%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
Market Cap
$2.31M
MomentumView details →
1D Return
−37.11%
YTD Return
−94.61%
RSI (14)
20.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
Market Cap
$2.31M
RSI (14)
20.4
MomentumView details →
1D Return
−37.11%
YTD Return
−94.61%
SummaryUpdated Jun 1, 2026
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is a commercial-stage biopharmaceutical company founded in 2017 and headquartered in New Haven, Connecticut. The company went public in March 2018 and specializes in developing treatments for neurological and psychiatric conditions using artificial intelligence and machine learning approaches. BioXcel's flagship product, IGALMI, received FDA approval for treating acute agitation associated with schizophrenia and bipolar disorders, marking the company's transition from a pure development-stage entity to a commercial operation.
Similar companies
Latest newsMore news →
BioXcel Therapeutics entered into a super-priority senior secured priming debtor-in-possession credit agreement providing up to $77.25 million in aggregate principal, including $19 million new money loans and $58.25 million roll-up loans, with an initial draw of $9.5 million.4d agoTeva Pharmaceutical Industries has made a bid to acquire certain assets of BioXcel Therapeutics, including the product Igalmi and a potential at-home agitation treatment, to expand its neuroscience portfolio.4d agoBioXcel Therapeutics entered into an asset sale agreement with Teva Pharmaceuticals, which will act as the stalking horse bidder in a court-supervised 363 auction process.8d ago